标题
Emerging strategies to overcome resistance to endocrine therapy for breast cancer
作者
关键词
Breast cancer endocrine therapy resistance, Estrogen receptor, Growth factor signaling, Breast cancer targeted therapy, Signaling cross talk and pathway-driven breast cancer agents
出版物
CANCER AND METASTASIS REVIEWS
Volume 33, Issue 2-3, Pages 791-807
出版商
Springer Nature
发表日期
2014-06-19
DOI
10.1007/s10555-014-9504-6
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Modulation of BAG-1 Expression Alters the Sensitivity of Breast Cancer Cells to Tamoxifen
- (2014) Hong Liu et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- New and emerging HDAC inhibitors for cancer treatment
- (2014) Alison C. West et al. JOURNAL OF CLINICAL INVESTIGATION
- Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
- (2014) Ingrid A. Mayer et al. JOURNAL OF CLINICAL ONCOLOGY
- Dasatinib-Letrozole Gets Split Verdict
- (2014) Cancer Discovery
- The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer
- (2013) Yan Ni Loh et al. BMC CANCER
- Co-targeting estrogen receptor and HER2 pathways in breast cancer
- (2013) Arjun Mehta et al. BREAST
- S6K1 inhibition enhances tamoxifen-induced cell death in MCF-7 cells through translational inhibition of Mcl-1 and survivin
- (2013) Sung-Eun Hong et al. CELL BIOLOGY AND TOXICOLOGY
- Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
- (2013) A. Gucalp et al. CLINICAL CANCER RESEARCH
- AGR2 Predicts Tamoxifen Resistance in Postmenopausal Breast Cancer Patients
- (2013) Roman Hrstka et al. DISEASE MARKERS
- Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer
- (2013) Andrea Rocca et al. EXPERT OPINION ON PHARMACOTHERAPY
- Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor
- (2013) Denise A. Yardley et al. JOURNAL OF CLINICAL ONCOLOGY
- Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial
- (2013) John FR Robertson et al. LANCET ONCOLOGY
- Activating ESR1 mutations in hormone-resistant metastatic breast cancer
- (2013) Dan R Robinson et al. NATURE GENETICS
- Endoxifen’s Molecular Mechanisms of Action Are Concentration Dependent and Different than That of Other Anti-Estrogens
- (2013) John R. Hawse et al. PLoS One
- Efficacy of Histone Deacetylase and Estrogen Receptor Inhibition in Breast Cancer Cells Due to Concerted down Regulation of Akt
- (2013) Scott Thomas et al. PLoS One
- Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
- (2013) Shunqiang Li et al. Cell Reports
- CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling
- (2012) A Dubrovska et al. BRITISH JOURNAL OF CANCER
- AIB1:ER Transcriptional Activity Is Selectively Enhanced in Aromatase Inhibitor-Resistant Breast Cancer Cells
- (2012) J. O'Hara et al. CLINICAL CANCER RESEARCH
- Inhibiting HSP90 to Treat Cancer: A Strategy in Evolution
- (2012) L. Whitesell et al. CURRENT MOLECULAR MEDICINE
- Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
- (2012) Thomas Bachelot et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
- (2012) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Improving Endocrine Therapy for Breast Cancer: It's Not That Simple
- (2012) E. Claire Dees et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Estradiol receptors in breast cancer cells: Associated co-factors as targets for new therapeutic approaches
- (2012) Jack-Michel Renoir STEROIDS
- Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial
- (2011) J. Huober et al. BREAST
- A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
- (2011) P N Munster et al. BRITISH JOURNAL OF CANCER
- Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor-Positive Metastatic Breast Cancer: A Randomized Phase II Study
- (2011) C. K. Osborne et al. CLINICAL CANCER RESEARCH
- Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer
- (2011) C. A. Lange et al. ENDOCRINE-RELATED CANCER
- Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer
- (2011) C. Thangavel et al. ENDOCRINE-RELATED CANCER
- Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer
- (2011) Todd W. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Incidence of Breast Cancer in the United States: Current and Future Trends
- (2011) W. F. Anderson et al. JNCI-Journal of the National Cancer Institute
- Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study
- (2011) Laura C Collins et al. MODERN PATHOLOGY
- Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
- (2011) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo
- (2010) Yi Chen et al. BREAST CANCER RESEARCH AND TREATMENT
- Elevated Src kinase activity attenuates tamoxifen response in vitro and is associated with poor prognosis clinically.
- (2010) Liam Morgan et al. CANCER BIOLOGY & THERAPY
- Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer
- (2010) M. Cristofanilli et al. CLINICAL CANCER RESEARCH
- Estrogen Receptors: Therapies Targeted to Receptor Subtypes
- (2010) S Nilsson et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Growth factor stimulation induces a distinct ER cistrome underlying breast cancer endocrine resistance
- (2010) M. Lupien et al. GENES & DEVELOPMENT
- Coprescription of Tamoxifen and Medications That Inhibit CYP2D6
- (2010) Kostandinos Sideras et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
- (2010) Jack Cuzick et al. LANCET ONCOLOGY
- Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
- (2010) J L Dean et al. ONCOGENE
- Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells
- (2009) Francesca De Amicis et al. BREAST CANCER RESEARCH AND TREATMENT
- Histone deacetylase inhibitor induced modulation of anti-estrogen therapy
- (2009) Scott Thomas et al. CANCER LETTERS
- The Tamoxifen Metabolite, Endoxifen, Is a Potent Antiestrogen that Targets Estrogen Receptor for Degradation in Breast Cancer Cells
- (2009) X. Wu et al. CANCER RESEARCH
- Combined Src and Aromatase Inhibition Impairs Human Breast Cancer Growth In vivo and Bypass Pathways Are Activated in AZD0530-Resistant Tumors
- (2009) Y. Chen et al. CLINICAL CANCER RESEARCH
- Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC
- (2009) P. Munster et al. CLINICAL CANCER RESEARCH
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
- (2009) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
- (2009) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells
- (2008) S. Hiscox et al. BREAST CANCER RESEARCH AND TREATMENT
- A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study
- (2008) T. H. Luu et al. CLINICAL CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started